Paid Clinical Trials Quebec City
Discover 364 paid clinical trials in Quebec City, Quebec. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
PembrolizumabLong-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT03486873
Conditions
Solid Tumors
Hematologic Malignancies
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pembrolizumab
Standard of Care (SOC)
Lenvatinib
Olaparib
MK-4280
Cardiovascular InterventionA RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
Sponsor:
McMaster University
Location:
Code:
NCT03127631
Conditions
Prostate Cancer
Cardiovascular Disease
Eligibility Criteria
Sex: Male
Age: 45+
Healthy Volunteers: Not accepted
Interventions
Nutrition
Exercise
Smoking cessation
Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)
ACE inhibitor
SBRT & PembrolizumabSBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
Sponsor:
RTOG Foundation, Inc.
Location:
Code:
NCT03546582
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pembrolizumab
Stereotactic Body Radiation Therapy (SBRT)
UpadacitinibA Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Sponsor:
AbbVie
Location:
Code:
NCT05889182
Conditions
Hidradenitis Suppurativa
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Upadacitinib
Placebo
StatinsStatins for Venous Event Reduction in Patients With Venous Thromboembolism
Sponsor:
Ottawa Hospital Research Institute
Location:
Code:
NCT04319627
Conditions
Venous Thromboembolism
Blood Clot
Post Thrombotic Syndrome
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Rosuvastatin Calcium
Placebo Oral Tablet
AblationCharacterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation
Sponsor:
Ottawa Heart Institute Research Corporation
Location:
Code:
NCT03347227
Conditions
Atrial Fibrillation
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Catheter ablation
Upadacitinib vs. AdalimumabStudy to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Sponsor:
AbbVie
Location:
Code:
NCT05814627
Conditions
Rheumatoid Arthritis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Upadacitinib
Adalimumab
Upadacitinib Matching Placebo
Adalimumab Matching Placebo
Glittre ADL-testGlittre ADL-test: Responsiveness to Acute Bronchodilation in Chronic Obstructive Pulmonary Disease (COPD)
Sponsor:
Laval University
Location:
Code:
NCT03071731
Conditions
Chronic Obstructive Pulmonary Disease
Eligibility Criteria
Sex: All
Age: 40+
Healthy Volunteers: Not accepted
Interventions
Bronchodilators
Placebos
Pelvic Health RehabilitationPelvic Health Rehabilitation After Breast and Gynecologic Cancer
Sponsor:
Laval University
Location:
Code:
NCT06822582
Conditions
Gynecologic Cancers
Breast Cancer Female
Incontinence
Incontinence Bowel
Sexual Dysfunction
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pelvic Health Module
Sacituzumab Tirutecan & PembrolizumabA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT06312176
Conditions
Breast Neoplasms
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Sacituzumab tirumotecan
Pembrolizumab
Paclitaxel
Nab-paclitaxel
Capecitabine